Phio Pharmaceuticals (PHIO)
(Delayed Data from NSDQ)
$5.05 USD
-0.80 (-13.60%)
Updated Jul 12, 2024 03:57 PM ET
After-Market: $5.09 +0.04 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PHIO 5.05 -0.80(-13.60%)
Will PHIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHIO
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
Other News for PHIO
Phio Pharmaceuticals Shareholders Approve Key Proposals
Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying
Phio Pharmaceuticals files for $100M mixed shelf
Phio Pharmaceuticals files $100M mixed securities shelf